EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

HYDROXYCHLOROQUINE, FAVIPIRAVIR OR STANDARD CARE IN MANAGEMENT OF SARS-COV-2: A RETROSPECTIVE COHORT STUDY

Dr. Nada Bassam Rabie*, Dr. Hassan Mueed Alsharif, Dr. Fayez Bukhari, Dr. Sana’a Fageeh, Dr. Samia Bukhari, Dr. Sarah Tayeb, Dr. Ghadah Rayes, Dr.Ahmad Algarni, Dr. Naif Turki Marzooki, Dr. Abdulraheem Bayameen, Dr. Nayef Abdulrahman Aljohani, Dr. Ahamd Rasheed, Dr. Ali Awais, Dr. Waleed Elsayad, Dr. Fahdah Almutairii, Dr. Raghdah Faraj, Dr. Yasir Alard, Dr. Sahal Khojah, Dr. Nader Nabil Elbanhawy, Dr. Mohamed Elamin Boshara, Dr. Hussain Abdullah Abualola

ABSTRACT

Background: Despite the tremendous efforts to offer safe and effective treatment guides for patients with SARS-CoV-2 infection, no clear answers exist. Here we are studying two relatively safe medications that were previously recommended for SARS-CoV-2 treatment and comparing them with standard of care. Methods: This is a retrospective electronic chart review study on SARS-CoV-2 infected patients between June and August 2020. Patients were eligible if they fulfilled the following criteria: (1) Age more than 14 years old, (2) Have confirmed SARS-CoV-2 infection and (3) Symptomatic, regardless of severity. Results: A total of 361 patients were included in the study. The mean age was 53 years 16.8, with 204 (56.4%) males. Patients were selected to be distributed between the hydroxychloroquine/zinc (HCQ/Z), favipiravir and standard of care group at 1:1:2 ratio. Most patients become asymptomatic at day 14 (n=139, 39%). There was no statistically significant difference between the three groups in terms of symptom resolution. Favipiravir showed earlier virologic clearance (as early as day 5) as compared to HCQ/Z and standard of care groups, even though this difference was not statistically significant (36%, 28% and 30% respectively, P-value 0.866). More patients in the favipiravir group required ICU admission (7% for favipiravir, 3% for HCQ/Z and 5% for the standard of care group (P-value 0.343). Similarly, out of 12 deaths, 4 were in the favipiravir group, 8 in the standard of care group and none in the HCQ/Z group (P-value= 0.137). No sever side effect was reported in any of the treatment groups. Conclusions: Standard of care alone was shown to be as effective as HCQ/Z and favipiravir in terms of symptom control. Similarly, no difference could be appreciated in terms of number of ICU admission and mortality. Implementation of clear therapeutic guidelines are needed to better define the components and goals of the best supportive care.

Keywords: COVID-19, SARS-CoV-2, hydroxychloroquine, favipiravir.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR: NOVEMBER ISSUE PUBLISHED

    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )